47 results on '"PENNA, GIUSEPPA"'
Search Results
2. Telomerase and telomere biology in hematological diseases: A new therapeutic target
3. Vaccination of multiple myeloma: Current strategies and future prospects
4. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients
5. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
6. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report
7. Endoscopic mucosal resection of a large inflammatory fibroid polyp (Vanek’s tumor): a case report
8. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions
9. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
10. Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
11. Imatinib Mesylate Therapy Induces Reduction in Neutrophil Gelatinase-Associated Lipocalin Serum Levels and Increase in Leptin Concentrations in Chronic Myeloid Leukemia Patients in Molecular Remission
12. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
13. Cardiac Involvement in Patients With Hematologic Malignancies
14. Bisphosphonates Induce Apoptosis of Circulating Endothelial Cells in Multiple Myeloma Patients and in Subjects with Bisphosphonate-Induced Osteonecrosis of the Jaws
15. Epigenetic therapy in myelodysplastic syndromes
16. Serum levels of Interleukin-16 in a multiple myeloma patient with cutaneous involvement
17. JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis: The Role of Bone Marrow Biopsy for the Diagnosis of Myeloproliferative Disease
18. Absence of the V617F JAK2 Mutation in the Lymphoid Compartment in a Patient with Essential Thrombo- cythemia and B-Chronic Lymphocytic Leukemia and in Two Relatives with Lymphoproliferative Disorders
19. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration
20. AUTOLOGOUS STEM CELL TRANSPLANTATION (AutoSCT) FOLLOWED BY A NON-MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) AS CONSOLIDATION THERAPY FOR MULTIPLE MYELOMA (MM)
21. A STUDY OF FEASIBILITY AND TOXICITY OF MULTIPLE CYCLES OF HIGH-DOSE MELPHALAN (HDM) FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (APBSCT) IN ELDERLY PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
22. MOBILIZATION OF CD34+ CELLS BY GLYCOSYLATED AND NON-GLYCOSYLATED G-CSF IN HEALTHY DONORS: A COMPARATIVE STUDY
23. A TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOETIN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENT IN MULTIPLE MYELOMA PATIENTS
24. Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
25. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
26. The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets
27. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab
28. Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia
29. Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia
30. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia
31. Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)
32. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602
33. Increase in serum protein carbonyl groups is associated with more advanced stage of disease in multiple myeloma patients
34. Nanoparticles in Oncology: The New Theragnostic Molecules
35. Stevens–Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options
36. Increase of IL-17, IL-22 and IL-23 serum levels induced by immunoglobulin infusion for Parvovirus-B associated Pure Red Cell Aplasia in a renal transplant recipient
37. MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin’s variant of Richter’s syndrome
38. Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera
39. Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
40. High-Dose Chemotherapy with Mitoxantrone + Melphalan and Autologous Stem Cell Rescue in Metastatic Breast Cancer Patients: A Study of Feasibility and Tolerability
41. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
42. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
43. Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera.
44. Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.
45. Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
46. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
47. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.